David A. DeMicco
Pfizer (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy
Most-Cited Works
- → Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins(2012)789 cited
- → Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events(2014)579 cited
- → Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment(2008)470 cited
- → Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease(2010)431 cited
- → J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial(2010)364 cited
- → Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin(2011)329 cited
- → Body-Weight Fluctuations and Outcomes in Coronary Disease(2017)306 cited
- → Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins(2015)285 cited
- → Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)(2009)252 cited
- → Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes(2015)218 cited